{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-294454","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.643764+00:00","generated_at":"2026-05-16T16:54:06.615292+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test","bullets":["CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025","Reimbursement for NeXT Personal Single Plasma Test set at $1,164, available up to six years post-treatment","Medicare coverage for the NeXT Personal Dx test is available once per cancer diagnosis for stage II/III breast cancer"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-294454","json":"https://secwatch.observer/filing/0001193125-25-294454.json","markdown":"https://secwatch.observer/filing/0001193125-25-294454.md","text":"https://secwatch.observer/filing/0001193125-25-294454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/0001193125-25-294454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000119312525294454/d937100d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T16:54:06.615292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}